For example, Thomas et al33 have shown that NOS2 is highly expressed in different cancers and may be a powerful prognostic biomarker, and NOS2 polymorphisms could be used to predict whether metastatic CRC patients may benefit from first‐line chemotherapy.34 This evidence concerns the gene NOS2 and colorectal carcinoma.